All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to speak to Lionel Ades, Saint-Louis Hospital, Paris, FR. We asked: what is the benefit of adding pevonedistat to azacitidine in patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)?
What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?
In this video, Lionel Ades describes the results of the phase II study that evaluated this combination in patients who had not previously received hypomethylating agents and were ineligible for stem cell transplant. He describes the event-free survival results of the 120 patients enrolled in the study as well as the overall survival and duration of response in the three patient populations: high-risk MDS, high-risk AML or low blast AML.
FDA grants APG-115 orphan drug designation for the treatment of AML and MDS
A phase Ib study (NCT04275518), investigating APG-115 as a single agent or in combination with cytarabine or azacitidine for patients with relapsed/refractory (R/R) AML or...
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast AML, Mikkael Sekeres and colleagues designed the...
Subscribe to get the best content related to MDS delivered to your inbox